Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Candida spp. are common causes of bloodstream infections among hospitalized patients. Fluconazole (FLC) remains a first-line therapy for candidemia; and voriconazole (VRC), an expanded-spectrum triazole, was recently approved for the treatment of candidemia in nonneutropenic patients. In vitro studies have suggested that VRC has potent activity against Candida spp. with reduced susceptibilities to FLC. We present a case report of invasive candidiasis and candidemia due to a Candida glabrata isolate that developed resistance to all currently available triazole antifungals after a course of FLC treatment. This case prompted us to determine the frequency of cross-resistance among bloodstream Candida isolates collected during a recent 12-month period at a large, academic medical center. FLC MICs were determined for 125 of 153 isolates (81.7%). Thirty of 125 isolates (24%) were resistant or showed reduced susceptibilites to FLC (MICs ≥ 16 μg/ml). When 28 of these 30 isolates were tested for their VRC susceptibilities, 9 (32%) had MICs that were ≥2 μg/ml. Five of these nine isolates were C. glabrata , two isolates were Candida tropicalis , one isolate was Candida albicans , and one isolate was Candida parapsilosis . All five Candida krusei isolates tested had VRC MICs ≤0.5 μg/ml. These data have prompted the introduction of reflexive FLC susceptibility testing of first bloodstream Candida isolates at our institution. The case report and our data also suggest that VRC should be avoided as initial therapy in unstable patients with invasive candidiasis, particularly in the setting of prior azole exposure. Studies are needed to define the clinical significance of in vitro resistance to the newer antifungal agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 4×
“account for 9% of nosocomial bloodstream infections (BSIs), making Candida the fourth most common cause of nosocomial BSIs in the United States (23).”
BackgroundInfluentialGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“Current guidelines suggest that clinicians consider antifungals other than FLC as therapy for invasive candidiasis in patients who have had prior azole exposure and who are unstable or infected with species known to have reduced susceptibilities to FLC (12).”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385 · cited 2×
“albicans continues to account for more than half of all cases of candidemia (4, 14, 22), others have demonstrated that Candida species other than C.”
BackgroundMechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 2×
“glabrata isolates from hematopoietic stem cell transplant recipients receiving FLC prophylaxis showed that MICs doubled, on average, every 31 days (1).”
BackgroundPfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3137-3141.2004 · Cited by 66
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
“causing infection in patients with previous fluconazole exposure are very likely to show decreased susceptibility to voriconazole as well (1, 32, 42).”
BackgroundPfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Metadata
- Authors
- Magill, S. S., Shields, C., Sears, C. L., Choti, M., & Merz, W. G.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2006-02
- Volume
- 44
- Issue
- 2
- Pages
- 529-535
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2167143090
- Cited by
- 139
- References
- 10
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy. https://app.cochat.ai/papers/10.1128/jcm.44.2.529-535.2006
- The paper
- Magill, S. S., Shields, C., Sears, C. L., Choti, M., & Merz, W. G. (2006). Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.44.2.529-535.2006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.